Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Real-world evidence to guide healthcare policies in oncology

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Phospho-ERK levels as predictors for chemotherapy of rectal carcinoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Epigenetic therapy in hematological cancers

    Research output: Contribution to journalReviewResearchpeer-review

  2. Nasal insulin administration does not affect hepatic glucose production at systemic fasting insulin levels

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Mother-child transmission of epigenetic information by tunable polymorphic imprinting

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin's lymphoma. Improvements in overall survival have been observed with the introduction of rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), however, prognostic markers are still needed. Methylation of the death associated protein kinase (DAPK or DAPK1) gene and TP53 mutations are likely to have prognostic value in DLBCL. We have assessed TP53 mutations and allelic DAPK1 methylation patterns in a cohort of 119 DLBCL patients uniformly treated with R-CHOP-like regimens. We found that DAPK1 promoter methylation was associated with shorter overall survival (p=0.017) and disease-specific survival (p=0.023). In multivariate analyses DAPK1 methylation remained as an independent prognostic factor predicting disease-specific survival (p=0.038). When only considering individuals heterozygous for the rs13300553 SNP monoallelic methylation of the A-allele was associated with shorter overall- and disease-specific survival (p<0.001). Patients carrying both DAPK1 methylation and a TP53 mutation had an inferior survival compared to patients carrying only one of these molecular alterations, however, this was borderline statistically significant. Allele-specific DAPK1 methylation patterns were also studied in a cohort of 67 multiple myeloma patients, and all of the methylated multiple myeloma samples heterozygous for the rs13300553 SNP were methylated on both alleles.

Original languageEnglish
JournalOncotarget
Volume5
Issue number20
Pages (from-to)9798-810
Number of pages13
ISSN1949-2553
DOIs
Publication statusPublished - 30 Oct 2014

ID: 44704822